Document:

Exhibit 4.27

 

SECOND AMENDMENT TO 1.5% SENIOR CONVERTIBLE NOTE (RS-10)

 

This Second Amendment to 1.5% Senior Convertible
Note (RS-10) (this “Amendment”) is made and entered into as of May 12th, 2017, by and between Amyris, Inc.,
a Delaware corporation (the “Company”) and Total Raffinage Chimie S.A., as assignee of Total Energies Nouvelles
Activités USA SAS (the “Investor”).

 

RECITALS

 

WHEREAS, on March 21, 2016 the Company
issued to the Investor a 1.5% Senior Convertible Note (RS-10) in the principal amount of $3,700,000, as amended by that First Amendment
to 1.5% Senior Convertible Note (RS-10) dated February 27, 2017 (as amended, the “Note”).

 

WHEREAS, the Company and the Investor
desire to further amend the Note as set forth herein.

 

WHEREAS, pursuant to Section 7 of the
Note, the Note may be amended with the written consent of the Company and the Investor.

 

NOW, THEREFORE, for good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereby agree as follows:

 

		1.	References to the Note. All references to the Note as the “1.5% Senior Convertible
Note” shall be modified to “12% Senior Convertible Note.”

 

		2.	Amendment of Section 2(a) of the Note. Section 2(a) of the Note is hereby deleted
in its entirety and replaced with the following:

 

(a)                  Interest.
This Note shall bear interest (i) from the Issue Date to May 15, 2017 on the Face Amount at a rate per annum equal to 1.50% (subject
to Section 4(k)) and (ii) from May 16, 2017 to the Final Maturity Date on the Face Amount at a rate per annum equal to 12.00% (subject
to Section 4(k)). Interest on this Note shall accrue daily and be due and payable in arrears on (i) December 31, 2017 and (ii)
the Final Maturity Date, and at such other times as may be specified herein. All computations of interest shall be made on the
basis of a 360-day year and actual days elapsed (which results in more interest being paid than if computed on the basis of a 365-day
year). Notwithstanding the foregoing, if an Event of Default shall have occurred and be continuing this Note shall bear interest
on the Face Amount at a rate per annum equal to 13.50% (as may be further adjusted pursuant to Section 4(k)).

 

		3.	Amendment of Section 2(b) of the Note. Section 2(b) of the Note is hereby deleted
in its entirety and replaced with the following:

 

(b)                  Scheduled
Payment of Principal. Unless paid, converted or cancelled and extinguished earlier in accordance with the terms hereof, the
Company shall deliver to the Investor cash in the amount of the Face Amount, together with all

 

 

     

     

    

accrued and unpaid interest on this Note, on March 31,
2018 (the “Final Maturity Date”) and this Note shall be retired and canceled.

 

		4.	Amendment of Section 3(c)(iii) of the Note. Section 3(c)(iii) of the Note is hereby
deleted in its entirety and replaced with the following:

 

(iii)                  Upon
conversion of this Note in whole or in part in accordance with the provision of Section 3(c) of this Note, the Company shall pay
to the Investor, substantially concurrently with delivery of the shares of Common Stock issuable on such conversion (the “Conversion
Shares”), any accrued and unpaid interest, through the day preceding the Conversion Date, on the portion of the Face
Amount represented by this Note that has been so converted. In addition, upon conversion of this Note in whole or in part following
a Change of Control, the Company shall pay to the Investor, substantially concurrently with delivery of the Conversion Shares,
an amount in cash equal to the interest that would have accrued at a rate per annum equal to 12.00% from such Conversion Date through
the Final Maturity Date on the portion of the Face Amount represented by this Note that has been so converted if such Note (or
portion of the Note) had not been converted (“Make-Whole Interest”).

 

		5.	Amendment of Section 4(k) of the Note. Section 4(k) of the Note is hereby deleted
in its entirety and replaced with the following:

 

(k)                  Acceleration.
If any Event of Default occurs and is continuing, the Investor may declare this Note to be due and payable immediately. Notwithstanding
the foregoing, in the case of an Event of Default described in Section 4(i)(vii) or 4(i)(viii) with respect to the Company this
Note, to the extent outstanding, will become due and payable without further action or notice. The Investor may rescind an acceleration
and its consequences if the rescission would not conflict with any judgment or decree. Notwithstanding the foregoing (or anything
to the contrary in the Agreement), the sole remedy of the Investor for a failure by the Company to comply with Section 8.6(b) of
the Agreement shall, for the first 365 days after the occurrence of such failure, be the right, by notice to the Company by the
Investor, to increase in the rate of interest on this Note to 16.50% for the first 180 days of such failure, and to 19.50% thereafter
(which increased interest shall constitute liquidated damages for such failure).

 

		6.	Amendment of Exhibit 1 of the Note. All references in Exhibit 1 to the Note to the
“1.5% Senior Convertible Note due 2017” shall be replaced with “12% Senior Convertible Note due 2018.”
In addition, the signature block next to “Conversion Information” in Exhibit 1 to the Note is hereby deleted in its
entirety and replaced with the following:

 

	 	TOTAL RAFFINAGE CHIMIE S.A.:
	 	 	 	 
	 	By: 	 	 
	 	Print Name:	 
	 	Print Title:	 
	 	 	 	 
	 	Address:	 
	 	2, Place Jean Millier	 

 

     

     

    

 

	 	La Défense 6, 92400	 
	 	Courbevoie, France	 
	 	Attn:	 	 
	 	Fax. No.:	 
	 	Email:	 

 

		7.	Full Force and Effect. Except as expressly modified by this Amendment, the terms
of the Note shall remain in full force and effect.

 

		8.	Integration. This Amendment and the Note constitute the entire agreement and understanding
of the parties with respect to the subject matter hereof, and supersede all prior understandings and agreements, whether oral or
written, between or among the parties hereto with respect to the specific subject matter hereof.

 

		9.	Counterparts; Facsimile. This Amendment may be executed in one (1) or more counterparts,
each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Amendment
may be executed and delivered by facsimile, or by email in portable document format (.pdf), and delivery of any signature page
by such method will be deemed to have the same effect as if the original signature had been delivered to the other party.

 

[Remainder of Page intentionally
left blank]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

     

     

    

 

IN WITNESS WHEREOF, the parties hereto have
executed this Amendment as of the date first above written.

 

	AMYRIS, INC.	 
	 	 	 
	By: 	/s/ John Melo	 
	Name:	John Melo	 
	Title:	President and Chief Executive Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[Signature Page to Second Amendment to R&D Note]

 

     

     

    

 

 

IN WITNESS WHEREOF, the parties hereto have
executed this Amendment as of the date first above written.

 

 

	TOTAL RAFFINAGE CHIMIE S.A.	 
	 	 	 
	By: 	/s/ Nathalie Brunelle	 
	Name:	Nathalie Brunelle	 
	Title:	Deputy CEO

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[Signature Page to Second Amendment to R&D Note]Exhibit 4.53

 

 

Amyris, Inc.

5885 Hollis Street, Suite 100

Emeryville, California 94608

USA

 

May 4, 2017

 

Maxwell (Mauritius) Pte Ltd

60 B Orchard Road #06-18

Tower 2, The Atrium @ Orchard

Singapore 238891

Facsimile: (65) 6821 1188

 

SIDE LETTER

 

Reference is made to that certain (i) Maturity
Treatment Agreement, dated as of July 29, 2015 (the “Agreement”), by and among Amyris, Inc., a Delaware
corporation (the “Company”), and the investors listed on Schedule I thereto, including Maxwell (Mauritius)
Pte Ltd (“Temasek”) and (ii) that certain 6.50% Convertible Senior Note due 2019, in the principal amount
of $10,000,000 (No. A-1) (the “Note”), sold and issued by the Company to Temasek pursuant to that certain
Indenture between the Company and Wells Fargo Bank, National Association, dated May 29, 2014 (the “Indenture”).

 

In connection with the Agreement and the Note,
we are writing to you to confirm our mutual agreement on the issues set out below.

 

		1.	Definitions.

 

Capitalized terms used herein but not otherwise
defined shall have the meaning set forth in the Agreement.

 

		2.	Treatment of Note at Maturity.

 

		a.	The Company hereby agrees that, notwithstanding anything in the Agreement to the contrary, any
portion of the Note that remains outstanding on the maturity date of the Note (the “Maturity Date”),
together with accrued interest and any other amounts due under the Note or the Indenture, shall be paid by the Company in cash,
in the amount and on such terms as set forth in the Note.

 

		b.	For so long as it holds the Note, Temasek hereby waives all rights it has to convert any portion
of the Note into Common Stock of the Company pursuant to Article 6 of the Indenture and the corresponding provisions of the Note.

 

    	 	1	 

     

    

 

		c.	For the avoidance of doubt, notwithstanding anything in the Agreement to the contrary, the Company
agrees that Temasek shall not be required to convert any portion of the Note held by it that remains outstanding and has not been
converted or otherwise redeemed or exchanged as of or prior to the Maturity Date into shares of common stock of the Company.

 

		3.	Representations and Warranties.

 

		a.	The execution, delivery, and performance of this Side Letter by the Company has been duly authorized
by all requisite corporate action on the part of the Company, and this Side Letter constitutes the legal, valid, and binding obligations
of the Company enforceable in accordance with its terms, except (a) as limited by applicable bankruptcy, insolvency, reorganization,
moratorium, and other laws of general application affecting enforcement of creditors’ rights generally, and (b) as limited
by laws relating to the availability of specific performance, injunctive relief or other equitable remedies.

 

		b.	Except for any Current Report on Form 8-K to be filed by the Company in connection with the transactions
contemplated hereby, the Company is not required to give any notice to, make any filing with, or obtain any authorization, consent,
or approval of any government or governmental agency in order to consummate the transactions contemplated by this Side Letter.

 

		c.	The execution, delivery, and performance of this Side Letter by the Company will not conflict with,
require a consent, waiver or approval under, or result in a breach or default under, any of the terms of any agreement to which
the Company is a party or by which any of the Company’s assets are bound.

 

		4.	Miscellaneous.

 

		a.	This Side Letter shall be governed by and construed in accordance with the laws of the State of
Delaware applicable to contracts entered into therein, without reference to principles of choice of law or conflicts of laws that
might lead to the application of laws other than the laws of the State of Delaware.

 

		b.	Neither this Side Letter nor any right or obligations hereunder may be assigned or delegated by
any of the parties hereto without the written consent of the other parties hereto.

 

c.                     
This Side Letter may be executed in multiple counterparts, each of which will be deemed to be an original and all of which will
be deemed to be a single document.

 

    	 	2	 

     

    

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

 

Very truly yours,

 

Amyris, Inc.

 

 

	By:	/s/ John Melo	 

Name: John Melo

Title: President and CEO

 

 

 

 

 

 

 

 

 

 

 

    	 	3	 

     

    

 

Agreed and accepted by:

  

Maxwell (Mauritius) Pte Ltd

 

	By:	/s/ Chia Song Hwee	 

Name: CHIA SONG HWEE

Title: AUTHORIZED SIGNATORY

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}]]